Evidence map›Paper›PMID 40346275›Full record

ReviewNature reviews. Urology2025

Testosterone replacement therapy and spermatogenesis in reproductive age men.

Bryan D Naelitz, Leila Momtazi-Mar, Sanjay Vallabhaneni, Rossella Cannarella, Sarah C Vij, Neel V Parekh, Raevti Bole, Scott D Lundy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bryan D Naelitz *Department of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. naelitb2@ccf.org.ORCID 0000-0002-9268-3413
Leila Momtazi-Mar *Department of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0009-0001-1565-1151
Sanjay VallabhaneniNortheast Ohio Medical University, Rootstown, OH, USA.
Rossella CannarellaDepartment of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Sarah C VijUrology Section, Division of Surgical Subspecialties, University of Texas Health Austin, Austin, TX, USA.
Neel V ParekhDepartment of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Raevti BoleDepartment of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Scott D LundyDepartment of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-0127-4295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testosterone has a pivotal role in spermatogenesis, erectile function, libido and expression of secondary sexual characteristics. The prevalence of symptomatic, laboratory-proven testosterone deficiency increases with age and is often treated with testosterone replacement therapy (TRT). Treatment with exogenous androgens suppresses gonadotropin levels, inhibits endogenous testosterone production and drastically reduces intratesticular testosterone, consequently impairing spermatogenesis. Sperm production often slowly resumes after TRT cessation. However, the rate of recovery shows highly variable kinetics that might complicate family planning. Medical therapies (including aromatase inhibitors and selective oestrogen receptor antagonists) and exogenous gonadotropins (including human chorionic gonadotropin and follicle-stimulating hormone) may be used to preserve or restore spermatogenesis in select populations receiving TRT. Exogenous testosterone is contraindicated in men trying to conceive, but new short-acting formulations, including oral testosterone undecanoate and nasal testosterone gel, might incompletely suppress the hypothalamic-pituitary-gonadal axis and partially preserve spermatogenesis.

Indexed as

Hormone Replacement TherapyReproductionSpermatogenesisTestosteroneHumansHypogonadismMaleTestosterone

Identifiers

PMID40346275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.